Lilly Alimta Committee Review For Non-Small Cell Lung Cancer Set For July 27

This is a second indication for Alimta, which was approved Feb. 4 for the treatment of malignant pleural mesothelioma. Lilly said it is pleased with early uptake of Alimta; first quarter sales were $12 mil., including $7 mil. in initial stocking.

News Source: FDA Advisory Committee | Published: June 7, 2004 | Read Full Story

Contact an Asbestos and Mesothelioma Attorney, Lawyer, Law Firm

Please fill out the form below to contact an attorney. Provide as much information as possible to speed the processing of your inquiry (Only United States residents are eligible).

Contact Information
	*Are required items.
*First Name:
*Last Name:
Email Address:
*Daytime Phone:
Evening Phone:
*Zip Code:
Case Information
Have you, or the person you are contacting us on behalf of, been diagnosed with mesothelioma:
Yes: No:
Date of diagnosis:
*Comments: (Please describe your legal issues and needs.)
Terms
I understand submission of information submission of information for review does not create, is not intended to create, and must not be relied upon as creating, an attorney-client relationship. I understand such a relationship can only be created by the agreement of both the client and the attorney, evidenced by a written retainer agreement that has been signed by client and counter-signed by the attorney. By submitting your expression of interest you are consenting to receive telephone calls from participating law firms even if you are currently on the do-not-call list. *I Agree to these terms: